Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2025
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Longitudinal patient-reported outcomes and quality-of-life trajectories over 2 years in CAR-T therapy recipients.Blood neoplasia · 2026Trial
- Trial
- Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.Blood advances · 2026Trial
- Intelligent immunotherapy: AI-driven optimization of CAR-T therapy in hematologic malignancies.iScience · 2026Review
- Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States.Advances in therapy · 2026Article
- PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.European journal of nuclear medicine and molecular imaging · 2026Article
- A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.Blood cancer discovery · 2026Article
- Clinical Pharmacology of Lisocabtagene Maraleucel in B-cell Malignancies.Targeted oncology · 2026Review
- Beyond Survival: Measuring Treatment Tolerability with Patient-Reported Outcomes in the Lymphoma Immunotherapy Era.Current hematologic malignancy reports · 2026Review
- Health-related quality of life reporting in randomized controlled trials of chimeric antigen receptor T-cell therapy: A systematic review of dedicated publications.British journal of haematology · 2026Article
- A phase 1 study of R-GDP-venetoclax before autologous transplant in relapsed/refractory large B-cell lymphoma (CCTG LY.18).Blood neoplasia · 2026Article
- Autologous transplant for patients with chemotherapy-sensitive late relapse of diffuse large B-cell lymphoma.Blood neoplasia · 2026Article
- Autologous stem cell transplantation for secondary central nervous system lymphoma: a multicentre retrospective analysis.BMC cancer · 2026Article
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion · 2026Article
- Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells · 2026Review
- Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.Translational cancer research · 2026Article
- Naïve CD4Nature communications · 2026Article
- Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM.Blood advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large B-cell lymphoma (LBCL). Adults eligible for autologous stem cell transplantation (N = 184) were randomly assigned 1:1 to liso-cel (100 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.